<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354367</url>
  </required_header>
  <id_info>
    <org_study_id>C87058</org_study_id>
    <nct_id>NCT00354367</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas</brief_title>
  <official_title>A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's
      disease subjects with active draining fistulas.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Crohn Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with single or multiple fistulas, including perianal and enterocutaneous
             fistulas for at least 3 months as a complication of Crohn's disease

        Exclusion Criteria:

          -  Symptomatic obstructive intestinal strictures, bowel resection, proctocolectomy or
             total colectomy, abscesses present at screening, current total parenteral nutrition,
             short bowel syndrome.

          -  All the concomitant diseases or pathological conditions that could interfere with
             Crohn's disease assessment or to be harmful for the well being of the patient.

          -  Previous clinical trials and previous biological therapy that could interfere with the
             results in the present clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Krassimir Mitchev, MD</last_name>
    <role>Study Director</role>
    <affiliation>UCB / Global Medical Affairs</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <keyword>Crohn Disease</keyword>
  <keyword>Certolizumab pegol</keyword>
  <keyword>Fistula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

